Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Common Stock
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Common Stock Peer Comparison
Competitive Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
N
|
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
|
Common Stock
ÂĄ1.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Common Stock
ÂĄ52k
|
CAGR 3-Years
0%
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Common Stock
ÂĄ603.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Common Stock
ÂĄ6.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Common Stock
ÂĄ1.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Common Stock
ÂĄ401m
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Common Stock?
Common Stock
1.6B
CNY
Based on the financial report for Mar 31, 2024, Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Common Stock amounts to 1.6B CNY.
What is Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
24%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Nanjing King-friend Biochemical Pharmaceutical Co Ltd have been 20% over the past three years , 24% over the past five years .